Harbour BioMed Announces US IND Clearance of Its First ADC Program HBM9033 in Solid Tumors | Antibodies

Harbour BioMed Announces US IND Clearance of Its First ADC Program HBM9033 in Solid Tumors

Related Keywords

Suzhou ,Jiangsu ,China ,Netherlands ,United States ,Cambridge ,Cambridgeshire ,United Kingdom ,Jingsong Wang ,Drug Administration ,I Harbour Biomed The Company ,Harbour Biomed Announces ,Its First ,Solid Tumors ,Chinai August ,Harbour Biomed ,Chief Executive Officer ,Biologics ,Antibodies ,Therapeutic Antibodies ,Recombinant ,Antibody Drug Conjugates ,Dc ,Immunoconjugates ,Biosimilar Antibodies ,Biosuperior Antibodies ,Antibody Fragments ,Scfv ,Lab ,Nanobodies ,Domain Antibodies ,Manufacturing ,